Safety: No progression to muscle-invasive disease, no radical cystectomies, no grade 3 or higher treatment-related adverse events, and no interruptions or discontinuations due to adverse events; most treatment-related adverse events were grade 1.CR at any time: 95% overall (based on 38 patients) and 94% among BCG-unresponsive patients.Chief Medical Officer (Oncology/Urology) Dr. Raj Pruthi provided details on the 12-month dataset, describing NDV-01’s performance as a high response rate with durable efficacy ...